IKT (Inhibikase Therapeutics) Total Operating Expense: $55.80 Mil (TTM As of Mar. 2026)


IKT Inhibikase Therapeutics Inc IKT
33 GF Score
Price $1.99
! 1 Warning Sign
View Full Analysis

What is Inhibikase Therapeutics Total Operating Expense?

Inhibikase Therapeutics IKT +3.11% 33 Total Operating Expense is $55.80 Mil as of Mar. 2026. GuruFocus rates IKT with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Inhibikase Therapeutics's Total Operating Expense for the three months ended in Mar. 2026 was $18.22 Mil. Inhibikase Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $55.80 Mil.

Inhibikase Therapeutics Total Operating Expense Related Terms

Inhibikase Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Inhibikase Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibikase Therapeutics Total Operating Expense Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 14.77 18.13 20.09 28.59 53.35

Inhibikase Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.76 11.19 13.26 13.13 18.22
IKT
33GF Score
Inhibikase Therapeutics Inc IKT
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibikase Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $55.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $55.80 Mil mean?
Inhibikase Therapeutics (IKT) has a Total Operating Expense of $55.80 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Inhibikase Therapeutics and its competitors.
Is Inhibikase Therapeutics' Total Operating Expense too high?
Inhibikase Therapeutics' current Total Operating Expense is $55.80 Mil. Overall, Inhibikase Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Inhibikase Therapeutics' Total Operating Expense compare to FHTX and OBIO?
Inhibikase Therapeutics' Total Operating Expense of $55.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Inhibikase Therapeutics and its competitors. Inhibikase Therapeutics's current Total Operating Expense is $55.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibikase Therapeutics stock overvalued right now?
Inhibikase Therapeutics (IKT) has a current Total Operating Expense of $55.80 Mil. The current Total Operating Expense is $55.80 Mil. Inhibikase Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Inhibikase Therapeutics (IKT), the current Total Operating Expense is $55.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibikase Therapeutics Business Description

Address 1000 N. West Street, Suite 1200, Wilmington, DE, USA, 19801
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
33GF Score

Get the complete analysis for IKT

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.99
Price